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After spending 2 years at the Rockefeller University in New York, as a research associate in the
laboratory of Christian de Duve, I accepted an offer from Sandoz Ltd., which was attractive in
terms of space, equipment, and research facilities, and returned to Switzerland. Beatrice Dewald,
joined my laboratory after several years at NYU and Vanderbilt University, and we continued our
studies of the enzymes of neutrophil granulocytes initiated at Rockefeller, with particular attention
to neutral proteinases, their release and their role in tissue damage and inflammation.We went back
to academia in 1983, when I became director of the Theodor Kocher Institute, a unique institution
for graduate studies, associatedwith the Faculties of Sciences andMedicine of theUniversity of Bern,
which everybody called TKI. Theodor Kocher, both surgeon and scientist, was awarded the Nobel
Prize in 1909 “for his work on the physiology, pathology, and surgery of the thyroid gland.” He firmly
believed in the role of basic research for medical progress, and donated his prize money as an initial
contribution to the construction of a dedicated interfaculty institute.
At the TKI, research on human leukocytes in inflammation and host defense continued with
new colleagues, Alfred Walz, head of a laboratory for biochemistry and molecular biology, working
on interferon and cytokines, and two physicists, Dave Deranleau and Vinzenz von Tscharner, who
developed methods and instruments for the real-time analysis of cell activation. My experience in
the pharmaceutical industry was an asset, but the TKI had something more to offer: outstanding
Ph.D. students and postdoctoral fellows, a major resource for innovation. The young associates and
the students kept me close to the bench and open to lateral thinking.
I am expected to narrate how the first chemotactic protein was discovered. In Bern, it all began
with a surprising encounter. One evening, on the stairs of the TKI, I bumped into Paul Imboden,
a Ph.D. student in the laboratory of Alfred Walz, who told me he had found in human monocyte
cultures an agent that stimulates neutrophil leukocytes. No real surprise, there, I thought. Still,
I proposed to test on neutrophil leukocytes the effects of the new substance and of chemotactic
agonists that were known, i.e., C5a, fMet–Leu–Phe, platelet-activating factor, and leukotriene B4.
The new substance was a protein that triggered responses similar to those induced by common
chemotactic agonists, but acted through a yet unknown G-protein-coupled receptor. Unlike the
common agonists, which induce migration of different granulocytes and even of monocytes, the
novel protein was specific for neutrophils, and we thus called it NAF, for “neutrophil-activating
factor.” The observed selectivity for a single type of white cells was an important new finding. We
imagined, with some optimism, that NAF could be a prototype for a novel class of chemotactic
proteins, and thought that the search for proteins related to NAF was going to pay off. Analogs
were indeed identified, and the laboratories that pioneered such progress agreed to name the new
proteins “chemokines,” in abbreviation of “chemotactic cytokines.”
The characterization of NAF had to be completed first. Alfred Walz prepared a highly purified
sample of the protein, and I arranged for micro-sequencing at the Sandoz Research Institute in
Vienna. To our surprise, we were not alone! Between December 1987 and April 1988, the newly
discovered protein was presented in four independent papers (1–4). It was an unusual, choral
announcement of four matching partial amino-acid sequences. Furthermore, the sequence data
were in agreement with the cDNA-deduced sequence of a secretory protein of 99 residues that had
been published a few months before. The protein was homologous to β-thromboglobulin, but its
properties and function were not identified (5).
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FIGURE 1 | Shape change of neutrophils, the most elegant response to
chemo-attractants, observed within seconds of challenge, and
characterized by the protrusion and retraction of ectoplasmic
extensions, due to polymerization and breakdown of actin. The
protrusions appear to function like a swimmer’s arms and legs. Turbidity
recordings suggest that the changes are synchronized, possibly to facilitate
migration (11). Scanning electron micrograph by Matthias Wyman, a former
Ph.D. student at TKI, now professor at the University of Basel.
Ivan Lindley, Heinz Aschauer, and other colleagues at the
Sandoz Research Institute in Vienna, who had sequenced our
purified protein, went a few steps further. They synthesized a
gene coding for the 72-residue NAF, which they cloned and
expressed. The recombinant protein was analyzed at the TKI, and
found to be identical in activity and potency to purified, natural
NAF (6).
The first chemokine had been thoroughly characterized, but
still did not have a name. None of the acronyms used in the
papers reporting isolation, sequencing, cloning, and expression
(MDNCF, NAF, MONAP, LYNAP, etc.) being suitable, the new
protein ended up with a fancy but misleading name: “interleukin
8.” It was the first and the last chemokine to be taken for an
interleukin.
Four papers putting forward the same message indicated that
the chemokine area was important and competitive. I went to
Frederick to see Ed Leonard, Jo Oppenheim, and colleagues and
discuss possible collaborations. Forme, that visit was also a chance
to meet Teizo Yoshimura and Kouji Matsushima. We decided to
continue our friendly relations without a formal collaboration,
which was reasonable since there was no way of knowing how
things would develop in the field and how research in our lab-
oratories would evolve. In line with TKI traditions, we charac-
terized NAF/IL8 using biochemical and biophysical methods, as
shown in the comparison of neutrophil responses to NAF/IL8
and fMet–Leu–Phe by Thelen et al. (7). Real-time recordings of
changes in cell shape, cytosolic free calcium levels, superoxide for-
mation, and granule enzyme release showed that the responses to
both chemo-attractants followed similar kinetics. In addition, the
effects of both agonists were inhibited to a similar extent by pre-
treating the neutrophils withB. pertussis toxin and other inhibitors
of signal transduction. Despite the similarities in response quality,
we observed a clear difference between the two agonists in terms
of potency, with NAF/IL8 being 10–30 times more effective than
fMet–Leu–Phe.
I emphasized that NAF/IL8 is highly selective for neutrophils,
but I cannot end this brief account without pointing out that
the first chemokine had, in fact, additional attractant properties,
with unique scientific implications: for one thing, it attracted two
brilliant scientists from Vancouver to Bern, Bernhard Moser and
Ian Clark-Lewis. They were both primarily interested in NAF/IL8
and wanted to identify its receptor. They also expected to find
new chemokines and new receptors, and eventually to study the
structural determinants for receptor recognition and activation.
Bernhard Moser went to school in Bern, studied at ETH Zurich,
and obtained a PhD degree at the University of British Columbia
before returning to Bern to clone and characterize chemokine
receptors, and to study white cell traffic in immune defense. Ian
Clark-Lewis was introduced to immunology at the famous Walter
and Eliza Hall Institute of Medical Research in Melbourne and
specialized in chemical protein synthesis in the US and in Canada.
At the Biomedical Research Centre of the University of British
Columbia, he established an impressive facility for solid-phase
protein synthesis. Chemokines impressed him as a promising
area for studying structure-activity relations and for the design of
chemically-modified analogs including receptor antagonists.
From among the thirty and more publications witnessing the
productive collaboration between Ian, Bernhard and other sci-
entists at the TKI for more than a decade, I shall quote three
highlights relating to NAF/IL8. Early structure-activity relation
studies identified the short amino-terminal sequence preceding
the first cysteine as the site for receptor binding and triggering (8),
a principle that turned out to be valid for the whole chemokine
family, underscoring the prototypical value of NAF/IL8. A very
extensive study using a large sample of synthetic analogs with
single amino-acid exchanges revealed that except for the cysteines
and the ELR motif no other residue appeared to be required
for NAF/IL8 receptor binding and activity (9). The same study
showed, in addition, that IP10 (a CXC chemokine that does not
activate neutrophils) can be modified to a potent attractant of
neutrophils by insertion of discrete sequence domains taken from
the NAF/IL8 amino-terminal loop (9). Ian also answered a fun-
damental question that was raised after observing that NAF/IL8
forms dimers in solution: do chemokines act as monomers or
dimers? By replacing Leu in position 25 with N-methyl-Leu in
the NAF/IL8 sequence, he created a derivative that could not
dimerize but nevertheless retained full activity (10), indicating
that NAF/IL8 binds to its receptors and trigger responses as a
monomer. For BernhardMoser the work on IL8 and receptors was
a sort of high-level warming up. Bernhard’s major achievements
came a few years later, withMarcel Loetscher and Pius Loetscher as
associates, and several Ph.D. students, after moving on to arenas,
which were increasingly populated by lymphocytes.
Ian Clark-Lewis died prematurely in 2002. He is much missed
by those who worked with him, and saw him as a distinguished
TKI-member from theWest coast. He did not mind long-distance
travel, and visited us regularly. He frequently took time to discuss
scientific issues on the phone, in long, remarkable conversations.
From Vancouver, he had set up a productive network of contacts
and friendly relations with many of us.
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